Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial
Open accessThe DOI matches its Crossref record; 36 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study explored neoplasm risk with liraglutide versus placebo in the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) cohort. RESEARCH DESIGN AND METHODS: LEADER (NCT01179048) was an international, phase 3b, randomized, double-blind, controlled trial. Participants aged ≥50 years with type 2 diabetes and high cardiovascular risk were assigned 1:1 to receive liraglutide (≤1.8 mg daily; n = 4,668) or placebo (n = 4,672) in addition to standard care and monitored for 3.5–5 years (median follow-up 3.8 years). The occurrence of neoplasms was a prespecified, exploratory secondary end point. Post hoc analyses of the time to the first confirmed neoplasms were conducted using a Cox regression model. RESULTS: Neoplasm was confirmed in 10.1% of patients with liraglutide versus 9.0% with placebo (hazard ratio [HR] 1.12 [95% CI 0.99; 1.28]). The HR (95% CI) for liraglutide versus placebo was 1.06 (0.90; 1.25) for malignant neoplasms and 1.16 (0.93; 1.44) for benign neoplasms. Sensitivity analyses excluding neoplasms occurring <1 year or <2 years after randomization and analyses by sex provided similar results. In our main analyses, the 95% CI for the HR included one for all malignant neoplasms evaluated (including pancreatic and thyroid neoplasms) except for prostate neoplasms, which occurred in fewer liraglutide-treated patients. CONCLUSIONS: LEADER was not primarily designed to assess neoplasm risk. Firm conclusions cannot be made regarding numeric imbalances observed for individual neoplasm types (e.g., pancreatic cancer) that occurred infrequently. LEADER data do, however, exclude a major increase in the risk of total malignant neoplasms with liraglutide versus placebo. Additional studies are needed to assess longer-term exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among ∼4660 patients randomized to each group and followed for a median of 3.8 years, 5 patients in the liraglutide group and 3 patients in the placebo group received a thyroid cancer diagnosis (HR = 1.66 [CI 0.4–6.95]).33”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In fact, some studies exclude thyroid cases that are diagnosed too soon after drug exposure (e.g., <1 year). This consideration of a latency period can provide insight when distinguishing between a new diagnosis of preexisting thyroid cancer versus thyroid cancer carcinogenesis.33,38”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Overall, 10.1% of patients in the liraglutide group versus 9.0% in the placebo group had a neoplasm diagnosis (HR = 1.12 [CI 0.99–1.28]).”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“The potential trophic and carcinogenic effects of GLP-1 RA have been investigated across a series of primary sites, including thyroid and pancreatic cancer, with inconsistent results.29,33,34”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
The cited source says what the claim attributes to it.
In the citing paper
“RCT that evaluated the efficacy of GLP-1 RAs in individuals with diabetes or obesity have not shown a significantly increased risk of thyroid cancer.33,55,56”
From Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review (2024) · cites this paper as [33]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RAs) improve glycemic control with a low risk of hypoglycemia in people with type 2 diabetes (6).”
BackgroundSelf-citationBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“receptor expression has been reported in a wide range of rodent and human tissues, including the pancreatic islets, lung, heart, kidney, gastrointestinal tract, pituitary, skin, and several regions of the nervous system (7,8).”
BackgroundDistant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · cited 1×
“development of clinically evident pancreatic cancer is a process that takes many years (30).”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“Theprimary reports for ELIXA andEXSCEL did not include data specific to skin neoplasms (31,32).”
BackgroundEffects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · cited 1×
“Theprimary reports for ELIXA andEXSCEL did not include data specific to skin neoplasms (31,32).”
BackgroundSelf-citationVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 2×
“criticism on methodological grounds, suggested an increased risk for pancreatic tumors with incretin-based therapy (18,20,21), a recent large, international registry study did not confirm an increased risk of pancreatic cancer versus sulfonylureas (median follow-up 1.”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 2×
“receptor expression has been reported in a wide range of rodent and human tissues, including the pancreatic islets, lung, heart, kidney, gastrointestinal tract, pituitary, skin, and several regions of the nervous system (7,8).”
BackgroundType 2 diabetes and cancer: umbrella review of meta-analyses of observational studies
Tsilidis, K. K., Kasimis, J. C., Lopez, D. S., Ntzani, E. E., & Ioannidis, J. P. A. (2015) · BMJ · doi:10.1136/bmj.g7607 · Cited by 860
Adiposity and cancer at major anatomical sites: umbrella review of the literature
Kyrgiou, M., Kalliala, I., Markozannes, G., Gunter, M. J., Paraskevaidis, E., Gabra, H., Martin-Hirsch, P., & Tsilidis, K. K. (2017) · BMJ · doi:10.1136/bmj.j477 · Cited by 803
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Bethel, M. A., Patel, R. A., Merrill, P., Lokhnygina, Y., Buse, J. B., Mentz, R. J., Pagidipati, N. J., Chan, J. C., Gustavson, S. M., Iqbal, N., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30412-6 · Cited by 599 · cited 1×
“ing LEADER) also reported an absence of a significant effect for GLP-1RA on rates of pancreatic cancer and MTC, albeit with significant heterogeneity between the four eligible trials (33).”
BackgroundSelf-citationPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498 · cited 2×
“Results from large, prospective clinical trials may help clarify a potential risk for neoplasms with GLP-1RAs or other glucose-lowering medications (26).”
BackgroundButler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
Self-citationPancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D. H., & LeRoith, D. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0374 · Cited by 301 · cited 1×
“Glucose-lowering medications may also affect the risk of these events (1,3).”
BackgroundA Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.012 · Cited by 245 · cited 3×
“8 mg daily) or matched placebo as a subcutaneous injection, in addition to their standardof-care treatment (11,27).”
BackgroundMethodSelf-citationMatveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C. (2009) · Diabetes · doi:10.2337/db09-0058 · Cited by 242 · cited 1×
“tabase studies (20,21) have suggested an increase in the risk of thyroid cancer (16,20,21), pancreatic cancer (17,18,20, 21), intestinal neoplasms (15,19), and breast neoplasms (15) with the use of incretin-based therapy (GLP-1RAs and/or dipeptidyl peptidase 4 [DPP-4] inhibitors).”
BackgroundChen, Y., Wu, F., Saito, E., Lin, Y., Song, M., Luu, H. N., Gupta, P. C., Sawada, N., Tamakoshi, A., Shu, X.-O., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4229-z · Cited by 206
From obesity to diabetes and cancer: epidemiological links and role of therapies
García-Jiménez, C., Gutiérrez-Salmerón, M., Chocarro-Calvo, A., García-Martinez, J. M., Castaño, A., & De la Vieja, A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.37 · Cited by 172 · cited 1×
“Glucose-lowering medications may also affect the risk of these events (1,3).”
BackgroundExendin-4, a GLP-1 Receptor Agonist, Attenuates Prostate Cancer Growth
Nomiyama, T., Kawanami, T., Irie, S., Hamaguchi, Y., Terawaki, Y., Murase, K., Tsutsumi, Y., Nagaishi, R., Tanabe, M., Morinaga, H., et al. (2014) · Diabetes · doi:10.2337/db13-1169 · Cited by 136 · cited 1×
“In vitro studies have shown that liraglutide and exenatide significantly inhibit proliferation in human prostate cancer cell lines through GLP-1 receptor–dependent mechanisms (28,29), giving some plausibility to our observation.”
BackgroundTime-Dependent Risk of Cancer After a Diabetes Diagnosis in a Cohort of 2.3 Million Adults
Dankner, R., Boffetta, P., Balicer, R. D., Boker, L. K., Sadeh, M., Berlin, A., Olmer, L., Goldfracht, M., & Freedman, L. S. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv290 · Cited by 134 · cited 1×
“, due to gastrointestinal adverse events or weight loss observed with liraglutide), and a role for detection or surveillance bias in the relationship between diabetes and cancer has been suggested previously (35,36).”
BackgroundGLP-1R Agonists Promote Normal and Neoplastic Intestinal Growth through Mechanisms Requiring Fgf7
Koehler, J. A., Baggio, L. L., Yusta, B., Longuet, C., Rowland, K. J., Cao, X., Holland, D., Brubaker, P. L., & Drucker, D. J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.005 · Cited by 133 · cited 3×
“Preclinical data suggest that GLP-1RAs may have GLP-1 receptor-dependent intestinotrophic effects (19).”
BackgroundIncretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Myocardial infarction and future risk of cancer in the general population—the Tromsø Study
Rinde, L. B., Småbrekke, B., Hald, E. M., Brodin, E. E., Njølstad, I., Mathiesen, E. B., Løchen, M., Wilsgaard, T., Brækkan, S. K., Vik, A., et al. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0231-5 · Cited by 87
Funch, D., Gydesen, H., Tornøe, K., Major‐Pedersen, A., & Chan, K. A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12230 · Cited by 81 · cited 1×
“insurance claims database study that compared liraglutide with non–GLP-1–based therapy (median follow-up 15 months) (22).”
BackgroundZhao, M. H., Chen, J., Yuan, Y., Zou, Z., Lai, X., Rahmani, D. M., Wang, F., Yang, X., Huang, Q., & Bu, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-07921-2 · Cited by 77 · cited 1×
“A meta-analysis of randomized clinical trials of 24 weeks’ to 5 years’ duration showed that DPP-4 inhibitors were not associated with a significantly increased risk of developing malignant melanoma (25).”
Method(2016) · BMJ · doi:10.1136/bmj.i5340 · Cited by 51 · cited 1×
“Similar findings were reported from an observational study in GLP-1RA users (34).”
ResultThe temporal relationship between diabetes and cancer: A population‐based study
Lega, I. C., Wilton, A. S., Austin, P. C., Fischer, H. D., Johnson, J. A., & Lipscombe, L. L. (2016) · Cancer · doi:10.1002/cncr.30095 · Cited by 44
Li, X.-N., Bu, H.-M., Ma, X.-H., Lu, S., Zhao, S., Cui, Y.-L., & Sun, J. (2016) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0042-112368 · Cited by 36 · cited 1×
“In vitro studies have shown that liraglutide and exenatide significantly inhibit proliferation in human prostate cancer cell lines through GLP-1 receptor–dependent mechanisms (28,29), giving some plausibility to our observation.”
BackgroundCardiovascular safety and benefits of GLP-1 receptor agonists
Dalsgaard, N. B., Brønden, A., Vilsbøll, T., & Knop, F. K. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1281246 · Cited by 34
Htoo, P. T., Buse, J. B., Gokhale, M., Marquis, M. A., Pate, V., & Stürmer, T. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2068-3 · Cited by 25
Self-citation
Cited by
Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
Metadata
- Authors
- Nauck, M. A., Jensen, T. J., Rosenkilde, C., Calanna, S., Buse, J. B., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators
- Affiliations
- St. Josef-Hospital (DE)
- Novo Nordisk (Denmark) (DK)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-06-13
- Volume
- 41
- Issue
- 8
- Pages
- 1663-1671
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6463597
- OpenAlex
- W2807726778
- Semantic Scholar
- caf4b597cece1cdf24ad7c1a0f9d0f159ed8fa2c
- Cited by
- 94
- References
- 38
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 15 · 2023: 14 · 2022: 8 · 2021: 14 · 2020: 9 · 2019: 6 · 2018: 4
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001111)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- liraglutide, type 2 diabetes, cancer, benign tumors, GLP-1 receptor agonists, pancreatic cancer, thyroid cancer, prostate neoplasms, drug safety, LEADER trial
- MeSH terms
- Liraglutide, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Neoplasms, Placebos, Risk Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.